摘要
目的:探讨切除修复交叉互补基因1(excision repair cross complementary gene 1,ERCC1)和乳腺癌易感基因1(breastcancer susceptibility gene 1,BRCA1)在非小细胞肺癌(non-small cell lung cancer,NSCLC)术后患者给予铂类基础化疗方案后的预后价值。方法:收集我院2004-2008年间接受手术并确诊为NSCLC的80例患者的肺组织,利用免疫组织化学方法,检测80例肺癌组织及20例癌旁组织中ERCC1和BRCA1蛋白的表达情况;术后所有患者接受2周期以上铂类化疗方案,联合分析这两种蛋白的表达与患者化疗方案的选择、无瘤生存期(disease-free survival,DFS)及总生存时间(overall survival,OS)的关系。结果:①ERCC1和BRCA1在肺癌组织中的表达比癌旁组织中高,差异具有统计学意义(P=0.036,P=0.041);同时2种蛋白的表达与患者的年龄、性别、临床分期、病理类型等临床特征无关;②ERCC1低表达患者DFS和OS均长于ERCC1高表达患者(P=0.004,P=0.032);BRCA1的表达也得出相同的结论(P=0.023,P=0.006);③ERCC1和BRCA1同时低表达患者DFS和OS长于两种指标同时高表达的患者;④ERCC1和BRCA1同时低表达的患者中,接受含铂类化疗方案的患者受益最大。结论:ERCC1和BRCA1可作为NSCLC术后辅助化疗患者判断预后的有效指标,两种蛋白的高表达可能成为NSCLC术后铂类辅助化疗患者预后不良的预测因子。
Objective：To discuss the prognostic value of excision repair cross complementary gene 1 （ERCC1） and breast cancer sus- ceptibility gene 1 （BRCA1） in patients with non-small cell lung cancer（NSCLC） who received postoperative platinum-based chemother- apy. Methods：Lung tissues of 80 patients who were eventually diagnosed as NSCLC and were treated by surgery between 2004 and 2008 were collected. Protein expressions of ERCC1 and BRCA1 in lung cancer tissues of 80 NSCLC cases and in adjacent normal lung tissues of 20 cases were detcted by immunohistochemisty. All tissues came from patients with NSCLC who received at least two cycles of platinum-based postoperative adjuvant chemotherapy. Relationships between expressions of two proteins with choice of chemotherapy, disease-free survival（DFS）time and overall survival（OS） time were analyzed. Results：①Positive expression rates of ERCC1 and BRCA1 were significantly higher in lung cancer tissues than in adjuvant normal lung tissues with statistical differences （P=0.036, P=0.041 ）.Expressions of two proteins were not correlated with patients＇ age, sex, clinical stages and pathological classifi- cation. ②Patients in lower ERCC1 expression group had longer DFS time and OS time than those in higher expression group （P= 0.004, P=0.032） ;similar conclusion was drawn concerning expressions of BRCA1 （P=0.023,P=0.006）. ③Patients with lower ERCC1 and BRCA1 expressions had longer DFS time and OS time than those with higher expressions.④Patients in lower ERCC1 and BRCA1 expression group benefited most from cisplatin-based chemotherapy. Conclusions ： ERCC1 and BRCA1 could effectively estimate prognosis of NSCLC patients receiving postoperative adjuvant chemotherapy. Higher ERCC1 and BRCA1 expression may be predictior of patients with NSCLC who have adverse outcomes after postoperative adjuvant chemotherapy.
出处
《重庆医科大学学报》
CAS
CSCD
北大核心
2013年第5期517-522,共6页
Journal of Chongqing Medical University
基金
江西省教育厅科学技术研究资助项目(编号:GJJ10363)
关键词
非小细胞肺癌
切除修复交叉互补基因1
乳腺癌易感基因1
免疫组织化学
non-small cell lung cancer
excision repair cross complementary gene 1
breast cancer susceptibility gene 1
immunohis-toch emistry
